Keywords: Pfizer, Bristol-Myers Squibb, Eliquis, Blood thinner, Bayer, Xarelto, Boehringer, Pradaxa, VTE

Pfizer and B-MS’ blood thinner Eliquis better than expected in Ph III trial

Article | 24 June 2011

Print This

US drug majors Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) had a significant boost when they presented positive – ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in